KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership ...
Alessa Therapeutics (“Alessa”), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology ...
That small detail is going to be left to a 100-strong panel of random Brits, chosen to represent a cross-section of the population. They will decide which aspects of public life are most in need of ...
Poster Presentation Title: Real World Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab Presentation ...
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with ...
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the ...
Vista Equity Partners runs its private equity operations from Austin, with investments centered on enterprise software, data, and tech-focused companies. As of 2025, the firm reports over $100 billion ...
SAN JOSE, CA, UNITED STATES, February 24, 2026 / EINPresswire.com / — TapClicks, the leader in Smart Marketing solutions, today announced the launch of SmartStory, a new AI-powered solution that ...
SAN JOSE, CA, UNITED STATES, February 24, 2026 /EINPresswire.com/ — TapClicks, the leader in Smart Marketing solutions, today announced the launch of SmartStory, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results